CSS
EWTX icon

Cubist Systematic Strategies’s Edgewise Therapeutics EWTX Stock Holding History

Cubist Systematic Strategies’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-219,549
Closed -$5.86M – 3041
2024
Q4 		$5.86M Buy
+219,549
New +$6.99M 0.04% 737
2024
Q2 		– Sell
-103,208
Closed -$1.88M – 3286
2024
Q1 		$1.88M Buy
103,208
+101,479
+5,869% +$1.61M 0.01% 1689
2023
Q4 		$18.9K Buy
+1,729
New +$12.1K ﹤0.01% 3355
2022
Q4 		– Sell
-44,237
Closed -$435K – 4339
2022
Q3 		$435K Buy
44,237
+32,777
+286% +$331K ﹤0.01% 3271
2022
Q2 		$91K Sell
11,460
-28,843
-72% -$218K ﹤0.01% 4000
2022
Q1 		$391K Buy
+40,303
New +$519K ﹤0.01% 2683

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Cubist Systematic Strategies's EWTX Position: Q1 2025 in Review

Cubist Systematic Strategies sold out of Edgewise Therapeutics (EWTX) in Q1 2025, closing a stake of 219,549 shares — an estimated $5.86M sold.

Cubist Systematic Strategies first reported a position in EWTX in Q1 2022 and held it in 6 quarters. The position peaked at $5.86M in Q4 2024. 192 funds tracked by Wall St. Rank hold EWTX as of Q1 2025.

  • Cubist Systematic Strategies reported no remaining Edgewise Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 219,549 Edgewise Therapeutics shares in Q1 2025, an estimated $5.86M.
  • Cubist Systematic Strategies first reported a position in Edgewise Therapeutics in Q1 2022 and held it in 6 quarters.
  • Cubist Systematic Strategies's Edgewise Therapeutics position peaked at $5.86M in Q4 2024.
  • 192 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2025.

Based on Cubist Systematic Strategies's 13F filing for Q1 2025, filed 15 May 2025.